Overview of Mauna Kea Technologies' Liquidity for H2 2024
Mauna Kea Technologies has released its liquidity contract details for the second half of 2024. A collaborative contract with the brokerage firm Gilbert Dupont outlines the resources leading to this liquidity enhancement. According to the latest report, the liquidity account revealed minimal resources as of the end of the reporting period.
Liquidity Account Status
At the conclusion of the reporting period, the liquidity account showed:
- Number of Shares: 0 shares
- Cash Balance: €0
This stark contrast follows the firm’s previous statement that outlined more active liquidity management with the exchange of shares and monetary resources.
Detailed Trading Metrics for H2 2024
During the second half of 2024, the total trading activities within the liquidity framework resulted in impressive figures:
Buy Side Analysis
On the buy side, the company reported:
- Number of Shares Purchased: 987,283
- Total Cash Used: €349,091.29
- Number of Transactions: 1,734
Sell Side Breakdown
Conversely, the sell-side results included:
- Number of Shares Sold: 1,071,874
- Total Cash Received: €363,988.03
- Number of Transactions: 1,332
Previous Liquidity Position
A comparison to the previous half-year statement dated June 28, 2024, reveals a shift in liquidity metrics:
- Shares Held: 84,591
- Cash Balance: €19,043.09
This highlights a strategic adjustment in the company’s liquidity management policies and reflects an ongoing commitment to optimizing financial performance.
Initial Liquidity Contract Resources
On implementation of the liquidity contract, the initial resources were recorded as follows:
- Number of Shares: 7,558
- Cash Balance: €277,913.78
Conclusion and Future Outlook
As Mauna Kea Technologies moves forward, the data from H2 2024 serves as a crucial indicator of its liquidity strategies. The company remains poised for adjustments in its trading framework while focusing on stabilizing cash flows and share management to enhance overall growth prospects.
About Mauna Kea Technologies
Mauna Kea Technologies specializes in advanced medical devices, notably the Cellvizio platform. This innovative technology enables real-time cellular imaging, which significantly aids medical professionals in diagnosing and treating patients with various health issues. Such technological advancements are influencing global medical practices, allowing for more proactive health monitoring and operational efficiency.
Frequently Asked Questions
What is the status of the liquidity account as of December 2024?
The liquidity account showed 0 shares and a cash balance of €0 at the end of the reporting period.
How many shares were bought during the second half of 2024?
A total of 987,283 shares were purchased during this period.
How does the sell-side activity compare to the buy-side?
The sell-side transactions totaled 1,071,874 shares sold, exceeding the number bought, indicating a significant liquidity increase.
What was the cash balance at the previous half-year mark?
As of June 28, 2024, the cash balance was €19,043.09.
What is the primary product of Mauna Kea Technologies?
Mauna Kea Technologies is best known for its Cellvizio platform, which facilitates real-time cellular imaging in medical settings.
